GlassScriptPhysician profile
Raul Caudillo
NPI 1619589165
$3,959.00
in general payments reported to CMS, 2019-2025
25 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,911 · 2022: $1,219 · 2023: $227 · 2024: $222 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $519.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $478.80 | 2021-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $395.99 | 2021 | |
| Lilly USA, LLC | $382.16 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $337.48 | 2021-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $330.35 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $266.62 | 2022 | |
| Scilex Pharmaceuticals INC. | $149.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $142.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $127.46 | 2021-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $125.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.48 | 2022-2025 | Jardiance |
| Amarin Pharma, INC. | $97.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.02 | 2021-2025 | Capvaxive, Gardasil 9 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $47.08 | 2021-2024 | Collagenase Santyl |
| Sanofi-Aventis U.S. LLC | $45.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $38.57 | 2021-2022 | |
| Exact Sciences Corporation | $35.75 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.88 | 2022 | |
| Dexcom, INC. | $24.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.85 | 2022 | |
| Novo Nordisk INC | $16.38 | 2021 | |
| Tactile Systems Technology INC | $15.52 | 2024 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Caudillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.